CRIS Current Research Information System

PAOLINI, STEFANIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 11.905
NA - Nord America 11.862
EU - Europa 9.332
AF - Africa 865
Continente sconosciuto - Info sul continente non disponibili 649
SA - Sud America 646
OC - Oceania 19
Totale 35.278
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.641
CN - Cina 3.213
SG - Singapore 3.150
VN - Vietnam 2.962
GB - Regno Unito 2.613
SE - Svezia 1.535
IT - Italia 1.252
DE - Germania 1.101
HK - Hong Kong 640
IN - India 607
FR - Francia 562
RU - Federazione Russa 459
BR - Brasile 457
IE - Irlanda 305
KR - Corea 301
NL - Olanda 296
JP - Giappone 255
ZA - Sudafrica 237
UA - Ucraina 222
TG - Togo 182
EE - Estonia 161
GR - Grecia 160
FI - Finlandia 151
SC - Seychelles 137
CI - Costa d'Avorio 136
CA - Canada 123
CH - Svizzera 118
NG - Nigeria 113
BD - Bangladesh 109
JO - Giordania 98
BG - Bulgaria 88
AR - Argentina 85
IR - Iran 81
PH - Filippine 80
TR - Turchia 57
PL - Polonia 55
ES - Italia 52
BE - Belgio 51
ID - Indonesia 49
IQ - Iraq 48
TH - Thailandia 46
MX - Messico 42
AT - Austria 38
UZ - Uzbekistan 30
EC - Ecuador 27
PK - Pakistan 27
MY - Malesia 24
TW - Taiwan 24
HR - Croazia 23
PY - Paraguay 20
EU - Europa 19
SA - Arabia Saudita 18
AU - Australia 17
CO - Colombia 16
RO - Romania 15
VE - Venezuela 15
LB - Libano 13
LT - Lituania 13
CL - Cile 12
JM - Giamaica 12
EG - Egitto 11
CZ - Repubblica Ceca 10
KE - Kenya 9
MA - Marocco 9
PE - Perù 9
RS - Serbia 9
TM - Turkmenistan 9
AE - Emirati Arabi Uniti 8
PT - Portogallo 8
DZ - Algeria 7
KG - Kirghizistan 7
KZ - Kazakistan 7
OM - Oman 7
TN - Tunisia 7
CR - Costa Rica 6
MK - Macedonia 6
MU - Mauritius 6
QA - Qatar 6
TT - Trinidad e Tobago 6
AL - Albania 5
ET - Etiopia 5
IL - Israele 5
NI - Nicaragua 5
NP - Nepal 5
PA - Panama 5
PR - Porto Rico 5
AZ - Azerbaigian 4
BB - Barbados 4
HN - Honduras 4
LV - Lettonia 4
XK - ???statistics.table.value.countryCode.XK??? 4
BA - Bosnia-Erzegovina 3
LU - Lussemburgo 3
SI - Slovenia 3
CY - Cipro 2
DK - Danimarca 2
GE - Georgia 2
GT - Guatemala 2
GY - Guiana 2
HU - Ungheria 2
Totale 34.616
Salva come PNG Salva come JPEG
Città #
Southend 2.395
Singapore 2.208
Ashburn 1.213
Chandler 943
Fairfield 924
San Jose 727
Dong Ket 720
Hefei 628
Hong Kong 603
Houston 530
Wilmington 521
Ho Chi Minh City 484
Woodbridge 451
Hanoi 437
Ann Arbor 428
Seattle 421
Beijing 417
Santa Clara 411
Princeton 408
Cambridge 336
Boardman 302
Dublin 302
Seoul 240
Westminster 211
Nanjing 206
Lauterbourg 205
Bologna 198
Tokyo 188
Padova 183
Lomé 182
New York 173
Los Angeles 156
Abidjan 136
Medford 133
Helsinki 127
Milan 119
Dallas 112
Shenyang 100
Jinan 98
Amman 97
Bern 95
Saint Petersburg 95
Buffalo 91
Frankfurt am Main 90
Berlin 86
Sofia 86
Jacksonville 83
Hebei 78
São Paulo 78
Nanchang 73
Abeokuta 72
Redondo Beach 70
Turin 67
Munich 66
Da Nang 65
Haiphong 65
Changsha 64
Rome 60
Bremen 58
San Diego 58
Council Bluffs 57
Guangzhou 57
Bengaluru 56
Tianjin 56
Shanghai 55
Redwood City 53
Florence 52
Brussels 50
Zhengzhou 48
Jiaxing 43
Johannesburg 41
Athens 38
Orem 37
Falls Church 33
Hangzhou 33
London 33
Haikou 32
Redmond 32
Baghdad 31
Hải Dương 31
Mülheim 30
Warsaw 30
Biên Hòa 29
Chicago 29
Amsterdam 28
Norwalk 28
Paris 28
Phoenix 28
Istanbul 27
Toronto 27
Ningbo 26
Taiyuan 26
Tongling 25
Grafing 24
Kunming 24
Mahé 24
Montreal 24
San Francisco 24
Wuhan 24
Brooklyn 23
Totale 21.569
Salva come PNG Salva come JPEG
Nome #
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 356
A POLYMORPHISM IN THE CHROMOSOME 9P21 ANRIL LOCUS IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA SUSCEPTIBILITY 353
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 346
A NEW SUBSET OF ADULT B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENT WITH PREDNISONE-INDUCED MONOCYTIC DIFFERENTIATION? 341
Adult "Triple Negative" ACUTE Lymphoblastic Leukemia Genome Wide Characterization 324
A HIGH SENSITIVE NANOFLUIDIC ARRAY IMPROVES THE DETECTION OF RARE COPIES OF BCR-ABL1 TRANSCRIPT IN PATIENTS WITH PHILADELPHIA POSITIVE (PH+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) 319
Chromothripsis in acute myeloid leukemia: Biological features and impact on survival 308
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia 288
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 285
EFFICACY, FEASIBILITY AND SAFETY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): THE BOLOGNA EXPERIENCE 276
A miRNA screening identifies miR-192-5p as associated with response to azacitidine and lenalidomide therapy in myelodysplastic syndromes 275
Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients 274
Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient. 269
Efficacy and clinical outcome of Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with second generation tyrosine kinase inhibitors (TKIs): The Bologna experience 269
Prolonged low-dose azacitidine schedule in high-risk MDS patients: Hematologic and molecular response 258
CDKN2A/B alterations impair prognosis in adult BCR-ABL1-positive acute lymphoblastic leukemia patients. 257
The alteration in key regulator genes of autophagy is mainstream mechanism of therapy resistance and impact prognosis of acute myelogenous leukemia (AML): results from diagnosis genomic analysis on 148 consecutive patients treated with intensive chemotherapy and long-term survival follow-up 257
Blinatumomab Is Safe and Effective in Relapsed and MRD Positive B-ALL CD19+ Patients: The Bologna Compassionate Program Experience 254
Alterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 250
Susceptibility to Philadelphia-Positive acute Lymphoblastic Leukemia (ALL) Is Associated with a Germline Polymorphism In the ANRIL (CDKN2BAS) Locus. 247
Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia 241
Assessment of liver stiffness measurement and ultrasound findings change during inotuzumab ozogamicin cycles for relapsed or refractory acute lymphoblastic leukemia 240
Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia 239
Chromothripsis in Acute Myeloid Leukemia Is Strongly Associated with Poor Prognosis and TP53 Alterations 236
Identification of A Pharmacogenomic Profile Associated with High Sensitivity and Low Toxicity to a Combination of Gemtuzumab Ozogamicin Plus Fludarabine, Cytarabine, Idarubicin Regimen In CD33-Positive Acute Myeloid Leukemia (AML) Patients 235
MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia 232
WHOLE TRANSCRIPTOME DEEP-SEQUENCING IDENTIFIES NOVEL POINT MUTATIONS, GENE EXPRESSION AND ALTERNATIVE SPLICING PROFILES IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA 230
Clonal activation of Akt in low-risk MDS patients with del(5q) treated with lenalidomide 229
AZACITIDINE IN MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF LONG-RESPONDER PATIENTS 229
Philadelphia positive (Ph+) acute lymphoblastic leukemia (ALL) patient with breast infiltration 229
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF BY GENOMIC DELETIONS IS A FREQUENT EVENT IN ADULT BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS AND CONTRIBUTES TO DISEASE PROGRESSION 225
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 224
AZACITIDINE FOR HIGH RISK MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE EVALUATION OF TWO DIFFERENT DOSING SCHEDULES 221
Use of a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript In Patients with Philadelphia-Positive Acute Lymphoblastic Leukemia (ALL). 221
AZACITIDINE IN HIGH AND LOW RISK MYELODYSPLASTIC SYNDROMES: RETROSPECTIVE EVALUATION OF 57 PATIENTS TREATED WITH 4 DIFFERENT THERAPEUTIC REGIMENS 220
Efficacy and Feasibility of Nelarabine Savage Therapy In Adult Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia (T-ALL) and Lymphoblastic Lymphoma (T-LBL) Strongly Indicates the Introduction of a Nelarabine-Based First Line Regimen 218
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 216
LOSS OF THE TUMOR SUPPRESSOR GENE CDKN2A/ARF IS FREQUENTLY DELETED BUT NOT MUTATED IN BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS 215
Distinct pattern of alterations in tp53 mutated and wild type acute myeloid leukemia (AML) patients 214
Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. 213
The clonal evolution of two distinct T315I-positive BCR-ABL1 subclones in a Philadelphia-positive acute lymphoblastic leukemia failing multiple lines of therapy: a case report 213
First Report of the Gimema LAL1811 Phase II Prospective Study of the Combination of Steroids with Ponatinib As Frontline Therapy of Elderly or Unfit Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia 211
Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters 210
Copy number variants signature in two patients with relapsed acute promyelocytic leukemia 209
Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents 206
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 206
A new biomarker of response to 5-azacitidine therapy in MDS and AML patients: SIRPB1 206
Early Increase of Phospholipase Cbeta1 (PI-PLCbeta1) Gene Expression Predicts Azacitidine Responsiveness in MDS Patients 204
A germline polymorphism in the ANRIL (CDKN2BAS) locus is associated with susceptibility to Philadelphia-positive acute lymphoblastic leukemia (ALL) 204
Deficient necroptosis pathway as a negative prognostic factor in acute myeloid leukemia. 204
Signaling pathways and bone marrow microenvironment in myelodysplastic neoplasms 203
BCR-ABL1-Positive Acute Lymphoblastic Leukemia Patients Treated with Only TKI Vs Conventional Chemo Plus TKI Therapy Show Similar DNA Alterations At Relapse Targeting Key Regulators of Tumor Suppression, Cell Cycle Control, and Lymphoid/B-Cell Development 203
ACTIVATION-INDUCED CYTIDINE DEAMINASE IS ABERRANTLY OVEREXPRESSED IN BCRABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA CELLS AND PROMOTES DNA-SINGLE STRAND BREAKS 201
Microarray analysis to identifiy novel copy number alterations in acute myeloid leukemia 200
BCR-ABL1 transcript detection in patients with Philadelphia-positive Acute Lymphoblastic Leukemia (ALL) using a new and high sensitive nanofluidic method 199
EFFICACY AND CLINICAL OUTCOME OF PHILADELPHIA (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) PATIENTS TREATED WITH SECOND GENERATION TYROSINE KINASE INHIBITORS (TKIS): THE BOLOGNA EXPERIENCE 198
Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia 197
Increased angiogenesis seems to correlate with inferior overall survival in myeloid sarcoma patients 196
The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukemia (ALL) patients treated with tyrosine kinase inhibitors 195
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II study 194
Impact on survival of catastrophic karyotype events in 101 consecutive acute myeloid leukemia (AML) patients: High risk karyotype and chromothripsis 193
SIRPB1 Is a Strong Predictor Biomarker of Response to 5-Azacitidine Therapy in MDS and AML Patients 190
Dissecting the Molecular Mechanisms of Aneuploidy in Acute Myeloid Leukemia By Next Generation Sequencing 190
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 190
Survival analysis of patients carrying different FLT3 mutations (internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations) in 459 consecutive non M3 newly diagnosed acute myeloid leukemia (AML) 189
Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature 189
SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. 186
Fludarabine, Cytarabine, Idarubicin and Etoposide (FLAIE) schedule is safe and active for young patients with newly diagnosed acute myeloid leukemia (AML): Results of a multicentric phase III Italian study 186
Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up 184
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 184
Molecular and chromosomal alterations: new therapies for relapsed acute myeloid leukemia. 183
Gemtuzumab-Ozogamicin Containing Regimens As Induction Therapy Give the Highest Complete Remission Rate and the Longest Overall Survival Compared with Other Induction Regimens in Patients with Newly Diagnosed Acute Myeloid Leukemia 183
FROM DIAGNOSIS TO RELAPSE: AN HIGH-RESOLUTION MOLECULAR ALLELOKARYOTYPING ANALYSIS OF PAIRED DIAGNOSIS-RELAPSE SAMPLES IN BCR-ABL1-POSITIVE ALL INDICATES INVOLVEMENT OF ALTERATIONS TARGETING KEY REGULATORS OF TUMOR SUPPRESSION, CELL CYCLE CONTROL, AND LYMPHOID/B CELL DEVELOPMENT 180
Very Poor Outcome and Chemoresistance of Acute Myeloid Leukemia Patients with TP53 Mutations: Correlation with Complex Karyotype and Clinical Outcome 179
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 178
EFFICACY AND FEASIBILITY OF NELARABINE SAVAGE THERAPY IN ADULT RELAPSED OR REFRACTORY T CELL ACUTE LYMPHOBLASTIC LEUKEMIA (T-ALL) OR LYMPHOBLASTIC LYMPHOMA (T-LBL): A SINGLE-CENTER EXPERIENCE 178
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 177
TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia 176
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 174
Two or More Chemotherapy Consolidation Courses, Followed By Autologous Bone Marrow Transplantation, and MRD Negativity, Give Long Term Overall Survival in Acute Myeloid Leukemia Patients 174
Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients 173
IKZF1 (IKAROS) Deletions Are Independent On BCR-ABL1 Rearrangement and Are Associated with a Peculiar Gene Expression Signature and Poor Prognosis in Adult B-Progenitor Acute Lymphoblastic Leukemia (ALL) Patients. 173
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 172
CLONAL ACTIVATION OF AKT IN LOW-RISK MDS PATIENTS WITH DEL(5Q) TREATED WITH LENALIDOMIDE 171
Dose increase of imatinib mesylate may overcome acquired resistance in bcr/abl-positive acute lymphoid leukaemia 171
Blastic plasmacytoid dendritic cell neoplasm: is it time to redefine the standard of care? 170
SNP array reveals a new deletion of JAK2 in AML patients 170
Efficacy of Azacitidine in the treatment of adult patients aged 65 years or older with AML 169
Extramedullary myeloid tumour of the stomach and duodenum presenting without acute myeloblastic leukemia: a diagnostic and therapeutic challenge. 168
You have accessAlterations in Pathways Regulating Phosphatidil Inositol 3 Phosphate (PI3P) Produce Both Cell Proliferation and Therapy Resistance, and Define a Group of Patients with Poor Prognosis in Acute Myeloid Leukemia (AML) 165
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 165
THE RS564398, A POLYMORPHISM IN “THE ANTISENSE NON-CODING RNA IN THE INK4 LOCUS”, ANRIL, IS ASSOCIATED TO PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) SUSCEPTIBILITY 164
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 164
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 164
Very poor outcome and chemoresistance of acute myeloid leukemia patients with TP53 mutations: Correlation with complex karyotype and clinical outcome 162
GENETIC VARIATIONS IN ADH1A AND CYP2E1 STRONGLY AFFECTS RESPONSE AND TOXICITY TO A COMBINATION OF GEMTUZUMAB OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN IN CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS 161
Use of a high sensitive nanofluidic array for the detection of rare copies of BCR-ABL1 transcript in patients with Philadelphia-positive acute lymphoblastic leukemia in complete response 160
Genomic wide microarray analysis identifies novel copy number alterations in adult acute myeloid leukemia 160
Survival analysis of 409 consecutive patients with newly diagnosed acute myeloid leukemia treated with intensive induction therapy, with or without the addition of gemtuzomab-ozagomicin (GO) 159
The PAX5gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemiabut is not associated with outcome. A report on behalf of the GIMEMA AcuteLeukemia Working Party 158
Totale 21.374
Salva come PNG Salva come JPEG
Categoria #
all - tutte 93.570
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 93.570
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224.285 463 82 275 431 413 288 71 273 209 331 736 713
2022/20234.321 490 673 227 546 347 326 149 260 690 83 333 197
2023/20241.192 54 194 52 130 85 256 74 65 56 69 88 69
2024/20254.433 192 694 366 299 611 224 401 124 49 373 246 854
2025/202610.796 894 1.124 943 769 1.156 549 1.015 436 2.300 906 343 361
2026/2027284 284 0 0 0 0 0 0 0 0 0 0 0
Totale 35.278